On February 14, 2024, AbbVie Inc. announced a significant leadership transition with Robert A. Michael set to succeed Richard A. Gonzalez as Chief Executive Officer (CEO), effective July 1, 2024. Gonzalez, who has been at the helm since AbbVie's inception in 2013, will retire from his CEO role and take on the position of Executive Chairman of the Board. Michael, currently serving as AbbVie's President and Chief Operating Officer, has a long history with the company, having held various leadership roles since joining Abbott in 1993, which later became part of AbbVie. The Board of Directors has also appointed Michael as a Class II director on the Board, coinciding with his CEO appointment. The announcement was made through a press release issued on February...Show More

On February 14, 2024, AbbVie Inc. announced a significant leadership transition with Robert A. Michael set to succeed Richard A. Gonzalez as Chief Executive Officer (CEO), effective July 1, 2024. Gonzalez, who has been at the helm since AbbVie's inception in 2013, will retire from his CEO role and take on the position of Executive Chairman of the Board. Michael, currently serving as AbbVie's President and Chief Operating Officer, has a long history with the company, having held various leadership roles since joining Abbott in 1993, which later became part of AbbVie. The Board of Directors has also appointed Michael as a Class II director on the Board, coinciding with his CEO appointment. The announcement was made through a press release issued on February 20, 2024, and is part of a planned succession to ensure a smooth transition of leadership. The company's press release highlighted Michael's significant contributions to AbbVie, including his involvement in key business development opportunities and navigating the end of exclusivity for Humira in the U.S. Gonzalez's tenure as CEO saw the company's market capitalization increase substantially, and he will continue to offer his experience as Executive Chairman.